Infective endocarditis complicating rituximab (anti-CD20 monoclonal antibody) treatment in an SLE patient with a past history of Libman–Sacks endocarditis: a case for antibiotic prophylaxis?
- 13 October 2005
- journal article
- case report
- Published by Springer Science and Business Media LLC in Clinical Rheumatology
- Vol. 25 (4), 583-584
- https://doi.org/10.1007/s10067-005-0031-2
Abstract
We report a 54 year old female whose successful treatment of cerebral lupus with rituximab was complicated by the development of streptococcus intermedius, on valves damaged by Libman-Sacks endocarditis more than 20 years previously.Keywords
This publication has 12 references indexed in Scilit:
- Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid ArthritisThe New England Journal of Medicine, 2004
- Successful long-term treatment of systemic lupus erythematosus with rituximab maintenance therapyLupus, 2003
- Experience with alemtuzumab plus rituximab in patients with relapsed and refractory lymphoid malignanciesBlood, 2003
- An open study of B lymphocyte depletion in systemic lupus erythematosusArthritis & Rheumatism, 2002
- Grand Rounds from International Lupus Centres Cardiac abnormalities in SLE: pancarditisLupus, 2000
- Proposed Modifications to the Duke Criteria for the Diagnosis of Infective EndocarditisClinical Infectious Diseases, 2000
- European Phase II Study of Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) for Patients With Newly Diagnosed Mantle-Cell Lymphoma and Previously Treated Mantle-Cell Lymphoma, Immunocytoma, and Small B-Cell Lymphocytic LymphomaJournal of Clinical Oncology, 2000
- The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK).2000
- Cardiac abnormalities in SLE: pancarditis.2000
- Clinically significant valvular heart disease in systemic lupus erythematosusAmerican Journal Of Medicine, 1988